(Q41737311)

8 October 2017

1 reference

title

Abciximab therapy in percutaneous intervention: economic issues in the United States (English)

1 reference

8 October 2017

A K Goklaney

1

1 reference

8 October 2017

J D Murphy

series ordinal

2

1 reference

8 October 2017

W B Hillegass

series ordinal

3

1 reference

8 October 2017

language of work or name

English

0 references

publication date

1 April 1998

1 reference

8 October 2017

published in

American Heart Journal

1 reference

8 October 2017

volume

135

1 reference

8 October 2017

issue

4

1 reference

8 October 2017

page(s)

S90-7

1 reference

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

Relation between activated clotting time during angioplasty and abrupt closure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

Safe use of platelet GP IIb/IIIa inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

Direct and indirect cost of percutaneous transluminal coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

Effects of coronary angioplasty, coronary bypass surgery, and medical therapy on employment in patients with coronary artery disease. A prospective comparison study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

Increased Risk of Non-Q Wave Myocardial Infarction After Directional Atherectomy Is Platelet Dependent: Evidence From the EPIC Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2898%2970301-1

10.1016/S0002-8703(98)70301-1

7 January 2021

Identifiers

DOI

1 reference

8 October 2017

1 reference